ASPIRE: Driving better outcomes
Wellinks' Aspire program addresses health outcomes for individuals with chronic conditions. The page also discusses strategies for wellness.

Wellinks provides virtual pulmonary rehabilitation and COPD management through a connected remote patient monitoring platform.
wellinks.comCrawled Oct 16, 2026
Wellinks' Aspire program addresses health outcomes for individuals with chronic conditions. The page also discusses strategies for wellness.
The POWER Study by Hartford HealthCare and Wellinks measures whether virtual COPD care can reduce COPD readmissions and hospital readmission rates for patients recovering at home.
The company discusses strategies, expert insights, and care approaches for COPD management and patient outcomes.
Wellinks' Predictive Patient Care model uses AI-driven analytics and tailored interventions to prevent complications, improve outcomes, and reduce costs.
A peer-reviewed study of Wellinks' virtual COPD management reports high engagement and satisfaction among older adults. The page also discusses digital tools for chronic respiratory care.
UMass Chan and Wellinks launch Healthy at Home, a virtual COPD management program studying how virtual care improves outcomes and reduces costs for people with COPD.
The page describes career opportunities at Wellinks and says its team works in respiratory care.
Wellinks' mission is to enhance lives through personalized virtual care for chronic respiratory conditions. The page also describes its values and approach to healthcare.
The page features testimonials from Wellinks users about improvements in their health and wellness through its personalized solutions.
Wellinks offers partnership opportunities and benefits for members, and has a Care Team.
Wellinks, a virtual-first cardiopulmonary care company, adds Andrew Agwunobi (MD, MBA) and Mike Waters to its board of directors. The company also expands its management team, though specific roles or new hires are not detailed in the announcement.
Wellinks raises **$10 million in Series B funding** from **UMass Memorial Health** and undisclosed investors to scale its **predictive cardiopulmonary care platform**. The company develops AI-driven tools for early risk assessment in heart and lung conditions, targeting hospitals and healthcare providers.
Wellinks, a virtual pulmonary rehabilitation provider, closes a $10 million Series B funding round with participation from UMass Memorial Health and inside investors. The company describes the financing as the first close of its Series B.
Wellinks and CareAbout Health are collaborating to expand value-based care for chronic obstructive pulmonary disease (COPD) patients in New Jersey and Florida. The partnership aims to improve access to coordinated, outcome-focused treatment programs for individuals managing COPD. Both organizations specialize in population health and care management solutions.
Wellinks acquires Spire Health to strengthen its position in predictive patient care for cardiopulmonary conditions. The move consolidates expertise in remote monitoring and AI-driven diagnostics for heart and lung health. Spire Health’s technology complements Wellinks’ existing platforms, aiming to improve early disease detection and patient outcomes. The combined entity now leads in digital health solutions for chronic respiratory and cardiovascular management.
SoNE Health partners with Wellinks to launch virtual care solutions for COPD patients starting September 29, 2024. The collaboration provides accessible rehabilitation programs and personalized support to improve health outcomes for individuals with chronic obstructive pulmonary disease (COPD). The initiative aims to deliver value-based care through digital health tools.
Wellinks introduces a virtual pulmonary rehabilitation program for UMass Memorial Health, providing COPD patients in Massachusetts with remote rehabilitation, continuous monitoring, and personalized care management services. The initiative expands access to specialized respiratory care through digital platforms, supporting patients who may face mobility or geographic barriers. Dedicated care teams oversee patient progress and coordinate follow-ups.
Wellinks appoints **Stacie Bratcher** as its new CEO. She joins the company with extensive healthcare experience to drive its focus on improving chronic respiratory care. The leadership change aims to strengthen the company’s mission in this specialized medical field.
Wellinks partners with Highmark Blue Cross Blue Shield Delaware to provide virtual pulmonary rehabilitation for members with COPD. The collaboration aims to lower access barriers by delivering specialized lung health services remotely. Virtual care options enhance convenience and continuity for patients managing chronic respiratory conditions.
Healthcare executive Douglas Wenners joins Wellinks’ board of directors, bringing over 25 years of experience to support the company’s focus on home-based COPD care solutions. His appointment aims to strengthen strategic leadership in expanding patient access to respiratory health services.
Wellinks acquires Sparo’s **Lift pulmonary rehabilitation program** to expand its virtual COPD management services. The integration enables patients to receive coordinated care and support for condition management at home. Wellinks combines this acquisition with its existing platform to strengthen remote pulmonary rehabilitation offerings.
Wellinks appoints Dr. Abi Sundaramoorthy as Chief Medical Officer to lead its virtual COPD management platform. Sundaramoorthy brings over a decade of healthcare experience to develop value-based care strategies. The company aims to enhance patient outcomes through its digital solution for chronic obstructive pulmonary disease (COPD).
Wellinks and the COPD Foundation collaborate to evaluate an integrated virtual COPD management solution. The collaboration is supported by Series C funding led by Morningside Ventures.
Wellinks raises $25 million in Series C funding for its virtual platform, which treats chronic obstructive pulmonary disease (COPD) through virtual care and connected medical devices. The devices link with an app, which is part of the company’s virtual solution for treating the condition.
Wellinks raises $25 million in Series C funding led by Morningside Ventures to expand its integrated virtual COPD management solution to more patients. The funding will support broader access to the solution.